Genmab A/SGMAB.CO
What Genmab A/S does.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue | DKK 5.4B | DKK 10.1B | DKK 8.4B | DKK 14.5B |
| Net income | DKK 2.2B | DKK 4.8B | DKK 3.0B | DKK 5.5B |
| Free cash flow | DKK 1.2B | DKK 6.1B | DKK 2.0B | DKK 3.6B |
More on GMAB.CO.
- Genmab A/S summary
- Genmab A/S financial statements
- Genmab A/S key metrics
- Genmab A/S health scores
- Genmab A/S valuation
- Genmab A/S dividends
- Genmab A/S peers
- Genmab A/S annual reports
Figures from Genmab A/S's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.